Profund Advisors LLC reduced its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 25.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,998 shares of the medical equipment provider’s stock after selling 2,333 shares during the period. Profund Advisors LLC’s holdings in Zimmer Biomet were worth $844,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Armor Investment Advisors LLC boosted its position in shares of Zimmer Biomet by 11.7% during the 4th quarter. Armor Investment Advisors LLC now owns 3,830 shares of the medical equipment provider’s stock worth $463,000 after purchasing an additional 400 shares in the last quarter. Daiwa SB Investments Ltd. boosted its position in shares of Zimmer Biomet by 5.2% in the 4th quarter. Daiwa SB Investments Ltd. now owns 8,470 shares of the medical equipment provider’s stock worth $1,022,000 after buying an additional 420 shares in the last quarter. Financial Counselors Inc. boosted its position in shares of Zimmer Biomet by 5.2% in the 4th quarter. Financial Counselors Inc. now owns 8,709 shares of the medical equipment provider’s stock worth $1,051,000 after buying an additional 431 shares in the last quarter. Creative Planning boosted its position in shares of Zimmer Biomet by 2.9% in the 4th quarter. Creative Planning now owns 15,765 shares of the medical equipment provider’s stock worth $1,902,000 after buying an additional 443 shares in the last quarter. Finally, Dorsey & Whitney Trust CO LLC boosted its position in shares of Zimmer Biomet by 0.9% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 49,118 shares of the medical equipment provider’s stock worth $5,926,000 after buying an additional 447 shares in the last quarter. Institutional investors own 86.51% of the company’s stock.
In other news, VP Chad F. Phipps sold 20,826 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $115.95, for a total transaction of $2,414,774.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Bryan C. Hanson acquired 25,077 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were bought at an average cost of $119.68 per share, with a total value of $3,001,215.36. The disclosure for this purchase can be found here. Corporate insiders own 1.07% of the company’s stock.
NYSE:ZBH traded down $3.17 on Friday, reaching $105.18. The stock had a trading volume of 861,253 shares, compared to its average volume of 1,193,736. Zimmer Biomet Holdings Inc has a 12-month low of $104.28 and a 12-month high of $133.49. The company has a current ratio of 1.50, a quick ratio of 0.81 and a debt-to-equity ratio of 0.76. The firm has a market cap of $21,367.00, a price-to-earnings ratio of 13.10, a price-to-earnings-growth ratio of 1.83 and a beta of 1.17.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, meeting the Zacks’ consensus estimate of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same quarter in the prior year, the company posted $2.14 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. equities research analysts forecast that Zimmer Biomet Holdings Inc will post 7.8 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio is currently 11.96%.
ZBH has been the topic of several recent research reports. BMO Capital Markets reiterated a “buy” rating and issued a $142.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, December 12th. Wells Fargo upgraded shares of Zimmer Biomet from a “market perform” rating to an “outperform” rating in a research report on Tuesday, December 19th. Oppenheimer reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Canaccord Genuity reiterated a “hold” rating and issued a $125.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Finally, Goldman Sachs upgraded shares of Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price objective on the stock in a research report on Tuesday, December 19th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $139.35.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/zimmer-biomet-holdings-inc-zbh-holdings-cut-by-profund-advisors-llc.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.